

Section	Reference	Page Name	Template	Migrate	New Copy	Description	Existing URL	Example URLs
Home Page	SCR_001	Home Page	TEM_001 :: Home Page		X	Having content on the Home page is new. It should showcase snapshots of the main site categories: About Us, Responsibility, Research & Development, Products, B2B, News & Careers	<a href="http://www.dsi.com/index.html">http://www.dsi.com/index.html</a>	
About Us	SCR_002	About Us	TEM_002 :: Portal Template	X	X	Introduction to: Our Vision & Values, Key Facts, Leadership, Awards & Recognition, History, Partnerships, Compliance, Diversity and Investors (Some of the original copy may be used)	<a href="http://www.dsi.com/about/index.html">http://www.dsi.com/about/index.html</a>	
	SCR_003	Our Vision & Values	TEM_003 :: Copy Template	X	X	Much of this content can be repurposed into the new template design.	<a href="http://www.dsi.com/about/ourvalues.html">http://www.dsi.com/about/ourvalues.html</a>	
	SCR_004	Key Facts	TEM_005 :: Key Facts Template		X	Include a brief company synopsis about DSI followed by information about Leadership, Headquarters, Number of Employees, 2009 Revenue, 2009 R&D Investment, Research Centers, Selected Key products, Awards (optional), Contact Information	New Page	<a href="http://www.bms.com/ourcompany/Pages/keyfacts.aspx">http://www.bms.com/ourcompany/Pages/keyfacts.aspx</a>
	SCR_005	Leadership	TEM_002 :: Portal Template		X	List of the DSI leaders. Include name, title and photo. A link to each executive's Bio page for each leader that could be linked to from the Leadership page.	New Page	<a href="http://www.bms.com/ourcompany/leadership/Pages/executive_committee.aspx">http://www.bms.com/ourcompany/leadership/Pages/executive_committee.aspx</a>
	SCR_006	Executive Officer Detail	TEM_003 :: Copy Template		X	Detailed executive biography template for each executive.	New Page	<a href="http://www.mccormickcorporation.com/OurCompany/CorporateGovernance/CorporateExecutiveOfficers/AlanDWilson.aspx">http://www.mccormickcorporation.com/OurCompany/CorporateGovernance/CorporateExecutiveOfficers/AlanDWilson.aspx</a>
	SCR_007	Awards & Recognition (Original) <i>(Contingent upon content)</i>	TEM_002 :: Portal Template		X	Highlighting Company Awards and Recognition	New Page	<a href="http://www.bms.com/responsibility/Pages/achievements.aspx">http://www.bms.com/responsibility/Pages/achievements.aspx</a>
	SCR_008	History	TEM_006 :: History Template		X	<p>Creating an expanded "History" section is a great opportunity for visitors to understand the rich company history, and provide considerable credibility. This section should contain an interactive timeline with engaging photos, imagery and content.</p> <p>It is important to establish the initial heritage and highlight past innovation and milestones in research. However, this should also focus on where DSI is today – and vision for the future.</p> <p><b><i>(Much of the content for this section can be pulled from the Corporate Profile document.)</i></b></p>	<a href="http://www.dsi.com/about/ourheritage.html">http://www.dsi.com/about/ourheritage.html</a>  <b>Interactive/Static Combination Option:</b> <a href="http://www.abott.com/global/ur/content/en_US/10.30.30/general_content/General_Content_00069.htm">http://www.abott.com/global/ur/content/en_US/10.30.30/general_content/General_Content_00069.htm</a> <a href="http://www.abott.com/global/ur/content/en_US/10.30.30/general_content/General_Content_00511.htm">http://www.abott.com/global/ur/content/en_US/10.30.30/general_content/General_Content_00511.htm</a>  <b>Non-interactive option:</b> <a href="http://www.bms.com/ourcompany/Pages/history.aspx">http://www.bms.com/ourcompany/Pages/history.aspx</a> <a href="http://www.mccormickcorporation.com/CorporateLayouts/companyHistory1890_1929.aspx">http://www.mccormickcorporation.com/CorporateLayouts/companyHistory1890_1929.aspx</a>	

Section	Reference	Page Name	Template	Migrate	New Copy	Description	Existing URL	Example URLs
	SCR_009	Partnerships	TEM_003 :: Copy Template		X	Provide an overview of DSI's partnership vision and strategy; a list of any partnerships (if appropriate) and contact information.	New Page	<a href="http://www.lilly.com/about/partnerships/">http://www.lilly.com/about/partnerships/</a>
REMOVED	SCR_010 REMOVED	Licensing (Contingent upon content) REMOVED -- DUE TO LACK OF CONTENT	N/A	N/A	N/A	Creating this page is dependant on whether or not we have enough usable copy.	N/A	
	SCR_011	Compliance & Ethics	TEM_003 :: Copy Template	X	X	Recreate this page and incorporate Ethics	<a href="http://www.dsi.com/about/compcompliance.html">http://www.dsi.com/about/compcompliance.html</a>	
		Daiichi Sankyo Shared Standards	PDF	X		PDF	<a href="http://www.dsi.com/documents/DaiichiSankyoSharedStandards.pdf">http://www.dsi.com/documents/DaiichiSankyoSharedStandards.pdf</a>	
		Standards of Business Conduct	PDF	X		PDF	<a href="http://www.dsi.com/documents/StandardsOfBusinessConduct.pdf">http://www.dsi.com/documents/StandardsOfBusinessConduct.pdf</a>	
		Annual Declaration of Compliance	PDF	X		PDF	<a href="http://www.dsi.com/documents/AnnualDeclarationOfCompliance_06302006.pdf">http://www.dsi.com/documents/AnnualDeclarationOfCompliance_06302006.pdf</a>	
		Core Values	PDF	X		PDF	<a href="http://www.dsi.com/about/ourvalues.html">http://www.dsi.com/about/ourvalues.html</a>	
		Compliance Leadership Program Brochure	PDF			PDF	<a href="http://www.dsi.com/documents/ComplianceLeadershipProgramBrochure.pdf">http://www.dsi.com/documents/ComplianceLeadershipProgramBrochure.pdf</a>	
	SCR_012	Information for Vermont Prescribers	TEM_003 :: Copy Template - Without Hero Image	X	X		<a href="http://www.dsi.com/about/infoforvermont.html">http://www.dsi.com/about/infoforvermont.html</a>	
REMOVED	SCR_013 REMOVED	Diversity	TEM_003 :: Copy Template	N/A	N/A	Overview of DSI's stand on Employee and Supplier Diversity		
	SCR_014	Supplier Diversity	TEM_003 :: Copy Template	X	X		<a href="http://www.dsi.com/about/diversity.html">http://www.dsi.com/about/diversity.html</a>	
		Letter to Contractors & Suppliers	PDF	X		PDF	<a href="http://www.dsi.com/documents/LettertoContractorsSuppliers_06Mar6.pdf">http://www.dsi.com/documents/LettertoContractorsSuppliers_06Mar6.pdf</a>	
		Supplier Policies: Shared Standards	PDF	X		PDF	<a href="http://www.dsi.com/documents/DaiichiSankyoSharedStandards.pdf">http://www.dsi.com/documents/DaiichiSankyoSharedStandards.pdf</a>	
	SCR_015	Supplier Registration	TEM_003 :: Copy Template - Without Hero Image	X			<a href="http://www.dsi.com/supplier/supplier.html">http://www.dsi.com/supplier/supplier.html</a>	
		Frequently Asked Questions	PDF	X		PDF	<a href="http://www.dsi.com/documents/FAQS.pdf">http://www.dsi.com/documents/FAQS.pdf</a>	
		Federal Contracting Designation Definition	PDF	X		PDF	<a href="http://www.dsi.com/documents/Federal_Contracting_Designation_Definition.pdf">http://www.dsi.com/documents/Federal_Contracting_Designation_Definition.pdf</a>	
	SCR_028	Business to Business	TEM_003 :: Copy Template		X			
	SCR_016	Investors	TEM_003 :: Copy Template		X	This page should provide general information about DSI and Daiichi Sankyo Co, LTD. Links to appropriate press releases, 2009 annual report and other information on the global Daiichi Sankyo Co, LTD Web site should be considered. Additional content may also include items such as pipeline information, patent expirations, etc.	New Page	Two samples: The Home Depot -- <a href="http://ir.homedepot.com/phoenix.zhtml?c=63646&amp;p=irol-irhome">http://ir.homedepot.com/phoenix.zhtml?c=63646&amp;p=irol-irhome</a> Lilly -- <a href="http://investor.lilly.com/index.cfm">http://investor.lilly.com/index.cfm</a>

Responsibility	SCR_017	Responsibility	TEM_002 :: Portal Template		X	Create an entirely new section dedicated to community involvement, environmental awareness, and corporate philanthropy. - Showcase community programs & corporate giving/philanthropy - Highlight key programs, such as the Patient Assistance Program (Cause marketing) - Highlight environmental programs & initiatives - Integrate employee programs, such as Volunteerism	New Page	Two samples: BMS -- <a href="http://www.bms.com/responsibility/Pages/home.aspx">http://www.bms.com/responsibility/Pages/home.aspx</a> Morgan Stanley -- <a href="http://www.morganstanley.com/globalcitizen/index.html">http://www.morganstanley.com/globalcitizen/index.html</a>
----------------	---------	----------------	----------------------------	--	---	---	----------	---

Section	Reference	Page Name	Template	Migrate	New Copy	Description	Existing URL	Example URLs
	SCR_018	Community	TEM_002 :: Portal Template		X	Create a new page that shares DSI's commitment to work with -- and help communities.	New Page	<a href="http://www.merck.com/responsibility/community/home.html">http://www.merck.com/responsibility/community/home.html</a>
REMOVED	SCR_019	Fellowship Program	TEM_003 :: Copy Template	X	X	Enhance this page by pulling in a few highlights from the Fellowship PDF that this page links to.	<a href="http://www.dsi.com/about/fellowships.html">http://www.dsi.com/about/fellowships.html</a>	
		Fellowship Brochure	PDF	X		PDF	<a href="http://www.dsi.com/documents/Fellowship_Brochure.pdf">http://www.dsi.com/documents/Fellowship_Brochure.pdf</a>	
	SCR_020	Office of CME	TEM_003 :: Copy Template	X			<a href="http://www.dsi.com/CME/index.html">http://www.dsi.com/CME/index.html</a>	
		Daiichi Sankyo-Lilly Grant Office (DSLGO)	PDF	X		PDF	<a href="http://www.dsi.com/documents/DSLGO_Brochure.pdf">http://www.dsi.com/documents/DSLGO_Brochure.pdf</a>	
		Certified Continuing Medical Education Overview	PDF	X		PDF	<a href="http://www.dsi.com/documents/OCME_Overview.pdf">http://www.dsi.com/documents/OCME_Overview.pdf</a>	
		Certified Continuing Medical Education Requirements	PDF	X		PDF	<a href="http://www.dsi.com/documents/OCME_Requirements.pdf">http://www.dsi.com/documents/OCME_Requirements.pdf</a>	
		Funding Request Application	WORD	X		Word Document	<a href="http://www.dsi.com/documents/Funding_Request_Application.doc">http://www.dsi.com/documents/Funding_Request_Application.doc</a>	
		Budget Proposal	EXCEL	X		Excel Spreadsheet	<a href="http://www.dsi.com/documents/OCME_Budget_Proposal.xls">http://www.dsi.com/documents/OCME_Budget_Proposal.xls</a>	
		DSI Letter of Agreement	PDF	X		PDF	<a href="http://www.dsi.com/documents/DSI_Letter_of_Agreement_OCME.pdf">http://www.dsi.com/documents/DSI_Letter_of_Agreement_OCME.pdf</a>	
		W-9 Form	PDF	X		PDF	<a href="http://www.dsi.com/documents/W9.pdf">http://www.dsi.com/documents/W9.pdf</a>	
		OCME Funding Application	PDF	X		PDF	<a href="http://www.dsi.com/documents/OCME_funding_applications.pdf">http://www.dsi.com/documents/OCME_funding_applications.pdf</a>	
		OCME FAQs	PDF	X		PDF	<a href="http://www.dsi.com/documents/OCME_FAQs.pdf">http://www.dsi.com/documents/OCME_FAQs.pdf</a>	
	SCR_021	Patient Assistance Program (Original)	TEM_003 :: Copy Template	X			<a href="http://www.dsi.com/news/patientassistance.html">http://www.dsi.com/news/patientassistance.html</a>	
	SCR_007	Awards & Recognition (Duplicate)	(Duplicate)		X	(Duplicate)	(Duplicate)	
Research & Development	SCR_022	Research & Development	TEM_002 :: Portal Template		X	Product Pipeline, Daiichi Sankyo Pharma Development, Daiichi Sankyo Research Institute, Disease Areas of Focus and other related items.	New Page	<a href="http://www.lilly.com/research/">http://www.lilly.com/research/</a>
	SCR_023	Product Pipeline (Original)	TEM_007 :: Pipeline Template		X	The existing table structure could be repurposed, but it would be optimal to make this page interactive.	<a href="http://www.dsi.com/products/pipeline.html">http://www.dsi.com/products/pipeline.html</a>	<a href="http://www.novartis.com/research/pharmaceutical-product.shtml">http://www.novartis.com/research/pharmaceutical-product.shtml</a>
	SCR_024	Daiichi Sankyo Pharma Development	TEM_003 :: Copy Template	X			<a href="http://www.dsi.com/research/pharmadev.html">http://www.dsi.com/research/pharmadev.html</a>	
	SCR_025	Daiichi Sankyo Research Institute	TEM_003 :: Copy Template	X			<a href="http://www.dsi.com/research/researchinstitute.html">http://www.dsi.com/research/researchinstitute.html</a>	
	SCR_026	Disease Areas of Focus	TEM_002 :: Portal Template		X	List of the key disease areas of focus.	New Page	<a href="http://www.nibr.com/research/disease/index.shtml">http://www.nibr.com/research/disease/index.shtml</a>
Products	SCR_027	Products	TEM_002 :: Portal Template	X	X		<a href="http://www.dsi.com/products/index.html">http://www.dsi.com/products/index.html</a>	
	SCR_023	Product Pipeline (Duplicate)	(Duplicate)	N/A	N/A	(Duplicate)	(Duplicate)	
	SCR_021	Patient Assistance Program (Duplicate)	(Duplicate)	N/A	N/A	(Duplicate)	(Duplicate)	
B2B MOVED	SCR_028	Business to Business MOVED UNDER "ABOUT US"	TEM_002 :: Portal Template CHANGED		X			<a href="http://www.boehringer-ingelheim.com/industrial_customer/biopharmaceuticals.html">http://www.boehringer-ingelheim.com/industrial_customer/biopharmaceuticals.html</a>
REMOVED	SCR_029	Employer	N/A	N/A	N/A	N/A		
REMOVED	SCR_030	Health Plan	N/A	N/A	N/A	N/A		
REMOVED	SCR_031	Physician Group	N/A	N/A	N/A	N/A		
REMOVED	SCR_032	Pharmacist	N/A	N/A	N/A	N/A		
REMOVED	SCR_033	Pharmacy	N/A	N/A	N/A	N/A		
REMOVED	SCR_034	Government	N/A	N/A	N/A	N/A		

Section	Reference	Page Name	Template	Migrate	New Copy	Description	Existing URL	Example URLs
News	SCR_035-111	News	TEM_002 :: Portal Template		X	This new page should provide users a consolidated view/landing page to see and access of all DSI's news items, including: General news, press releases, media content/contact information, upcoming events (if appropriate), and a few key Award/Recognition logos.		<a href="http://www.bms.com/News/Pages/home.aspx">http://www.bms.com/News/Pages/home.aspx</a>
	SCR_036	Press Releases	TEM_008 :: Press Releases Template		X			<a href="http://www.chevron.com/news/press/">http://www.chevron.com/news/press/</a>
	SCR_037	81 Individual Press Releases (Converted from PDF to HTML)	TEM_009 :: Press Release Details Template	X		Convert all press releases from PDF to HTML.		<a href="http://phx.corporate-ir.net/phoenix.zhtml?c=65454&amp;p=irol-newsArticle&amp;cat=news&amp;i=1408659">http://phx.corporate-ir.net/phoenix.zhtml?c=65454&amp;p=irol-newsArticle&amp;cat=news&amp;i=1408659</a>
	SCR_038	Publications	TEM_002 :: Portal Template		X			<a href="http://www.bms.com/news/publications/Pages/default.aspx">http://www.bms.com/news/publications/Pages/default.aspx</a> ; or <a href="http://www.chevron.com/news/publications/">http://www.chevron.com/news/publications/</a>
	SCR_039	Media	TEM_010 :: Media Template		X			<a href="http://www.mccormickcorporation.com/NewsRoom/NewsRoomMediaLibrary.aspx">http://www.mccormickcorporation.com/NewsRoom/NewsRoomMediaLibrary.aspx</a>
	SCR_040	Photos	TEM_011 :: Photos Template					<a href="http://www.mccormickcorporation.com/NewsRoom/NewsRoomMediaLibrary/NewsRoomMediaLibraryPhotos.aspx">http://www.mccormickcorporation.com/NewsRoom/NewsRoomMediaLibrary/NewsRoomMediaLibraryPhotos.aspx</a>

Contact Us	SCR_041	Contact Us (Original)	TEM_012 :: Contact Us	X	X	Most of the existing content can be used.	<a href="http://www.dsi.com/news/contacts.html">http://www.dsi.com/news/contacts.html</a>	
Search Results	SCR_042	Search Results Page	TEM_013 :: Search Results Template		X			<a href="http://www.inj.com/wps/wcm.jsp/showData.jsp?site=injcom_news&amp;q=product+pipeline">http://www.inj.com/wps/wcm.jsp/showData.jsp?site=injcom_news&amp;q=product+pipeline</a>
Site Map	SCR_043	Site Map	TEM_014 :: Site Map Template	X	X		<a href="http://www.dsi.com/sitemap.html">http://www.dsi.com/sitemap.html</a>	
Terms of Use and Privacy Policy	SCR_044	Terms of Use and Privacy Policy	TEM_003 :: Copy Template - Without Hero Image	X			<a href="http://www.dsi.com/terms.html">http://www.dsi.com/terms.html</a>	
Printer-Friendly	SCR_045	Printer-Friendly Page	TEM_015 :: Printer-Friendly Template		X	Strips out non-essential information to make a page printer-friendly.		
Side Wiki Disclaimer	SCR_046	Side Wiki Disclaimer	N/A		X			<a href="http://www.google.com/support/toolbar/bin/answer.py?answer=157270&amp;hl=en">http://www.google.com/support/toolbar/bin/answer.py?answer=157270&amp;hl=en</a>

## Existing Press Releases

- 1 SANKYO CO, LTD JOINS THE NATIONAL CHERRY BLOSSOM FESTIVAL IN WASHINGTON DC AS CENTENNIAL CELEBRATION COMMITTEE CO-CHAIR [view full story](http://www.dsi.com/news/pdfs/National_Cherry_Blossom_Press_Release.pdf)
- 2 Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs [view full story](http://www.dsi.com/news/pdfs/Feingold_release.pdf)
- 3 FDA Approves Benicar® for the Treatment of High Blood Pressure in Children and Adolescents aged 6-16 [view full story](http://www.dsi.com/news/pdfs/FINAL_Benicar_Pediatric_Approval_Press_Release.pdf)
- 4 DAIICHI SANKYO INITIATES LARGEST SINGLE, DOUBLE-BLIND, RANDOMIZED, PHASE III TRIAL FOR TREATMENT AND PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM [view full story](http://www.dsi.com/news/pdfs/HOKUSAI_kick_off_release_FINAL.pdf)
- 5 New Analysis Showed Effient® Cost-Effective Compared with Clopidogrel for Patients with Acute Coronary Syndromes Undergoing PCI [view full story](http://www.dsi.com/news/pdfs/Effient_Cost_Effectiveness_Data_Press_Release_US_F.pdf)
- 6 New Updates to AHA/ACC/SCAI Clinical Guidelines Recommend Treatment with Effient® for Patients with Acute Coronary Syndromes Managed with PCI [view full story](http://www.dsi.com/news/pdfs/ATT1824169.pdf)
- 7 Effient® Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease [view full story](http://www.dsi.com/news/pdfs/OPTIMUS_3_Press_Release_US_version_FINAL.pdf)
- 8 "Spirit of the Heart" Awareness Event Helps African Americans with Hypertension in Los Angeles County Take Charge of Their Heart Health [view full story](http://www.dsi.com/news/pdfs/FINAL_SoH_Los_Angeles_Press_Release.pdf)
- 9 Welchol® (colesevelam HCl) Receives FDA Approval to Lower LDL Cholesterol in Pediatric Patients with Heterozygous Familial Hypercholesterolemia [view full story](http://www.dsi.com/news/pdfs/Welchol_Ped%20Oral_Susp_Approvals.pdf)
- 10 Survivors of Heart Events: What Does it Take to Get Back to Living? [view full story](http://www.dsi.com/news/pdfs/Hearts_in_Harmony_Press_Release.pdf)
- 11 Effient™ is Now Available in Pharmacies [view full story](http://www.dsi.com/news/pdfs/Effient_Product_Availability_Release.pdf)
- 12 New Research Finds Dangerous Divide Between Physicians and Their Patients with Hypertension [view full story](http://www.dsi.com/news/pdfs/My_Pressure_Points_Physician_Release_FINAL.pdf)
- 13 Analysis OF Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing [view full story](http://www.dsi.com/news/pdfs/US_Press_Release_ISTH_018_Edoxaban.pdf)
- 14 Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient™ [view full story](http://www.dsi.com/news/pdfs/Final_Effient_FDA_Approval_Release.pdf)
- 15 Pressure is On for African Americans with Hypertension [view full story](http://www.dsi.com/news/pdfs/MPP_National_Consumer_Press_Release.pdf)
- 16 "Spirit of the Heart" Awareness Event in Baltimore Helps African Americans with Hypertension Take Charge of Their Heart Health [view full story](http://www.dsi.com/news/pdfs/Balt_release_final.pdf)
- 17 Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial [view full story](http://www.dsi.com/news/pdfs/Prasugrel_Universal_Definition_of_MI_Data_Release.pdf)
- 18 Two Studies at AACE 2009 Annual Meeting Highlight Effects of Welchol® (colesevelam HCl) on Blood Glucose and LDL-C in Patients with Type 2 Diabetes [view full story](http://www.dsi.com/news/pdfs/Welchol_AACE_Press%20Release.pdf)
- 19 Daiichi Sankyo, Inc. Celebrates the Growth of its U.S. Headquarters [view full story](http://www.dsi.com/news/pdfs/2_Hilton_Court_Alternate_Press_release.pdf)
- 20 AZOR® Receives FDA Approval as First-Line Treatment for High Blood Pressure [view full story](http://www.dsi.com/news/pdfs/FINAL%20AZOR_First_Line_Approval_Release.pdf)
- 21 New Data Shows AZOR® (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure [view full story](http://www.dsi.com/news/pdfs/AZTEC_Press_Release.pdf)
- 22 New Data Shows Blood Pressure Reduction Therapy with BENICAR® and BENICAR HCT® Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure [view full story](http://www.dsi.com/news/pdfs/BeniSILVER_Press_Release.pdf)
- 23 Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results [view full story](http://www.dsi.com/news/pdfs/ROADMAP_Press_Release.pdf)

Section	Reference	Page Name	Template	Migrate	New Copy	Description	Existing URL	Example URLs
	24	New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel view full story						<a href="http://www.dsi.com/news/pdfs/Prasugrel_TRITON_Genetics_Analysis_US.pdf">http://www.dsi.com/news/pdfs/Prasugrel_TRITON_Genetics_Analysis_US.pdf</a>
	25	European Commission Approves EFIENT® (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI view full story						<a href="http://www.dsi.com/news/pdfs/EFient_EU_Approval_Release021909.pdf">http://www.dsi.com/news/pdfs/EFient_EU_Approval_Release021909.pdf</a>
	26	Prasugrel Receives Unanimous Approval Recommendation from FDA Advisory Committee view full story						<a href="http://www.dsi.com/news/pdfs/Prasugrel_Ad%20Com_Recommended_Press_Release.pdf">http://www.dsi.com/news/pdfs/Prasugrel_Ad%20Com_Recommended_Press_Release.pdf</a>
	27	Notice Regarding the Acquisition of Shares in Zenotech Laboratories Limited view full story						<a href="http://www.dsi.com/news/pdfs/Zenotech_pressrelease.pdf">http://www.dsi.com/news/pdfs/Zenotech_pressrelease.pdf</a>
	28	Daiichi Sankyo, Inc. Establishes Subsidiary in Puerto Rico view full story						<a href="http://www.dsi.com/news/pdfs/Puerto_Rico_Opening.pdf">http://www.dsi.com/news/pdfs/Puerto_Rico_Opening.pdf</a>
	29	Daiichi Sankyo Records Valuation Loss, Goodwill Write-down, on Investment in Ranbaxy Laboratories view full story						<a href="http://www.dsi.com/news/pdfs/Goodwill_written_down.pdf">http://www.dsi.com/news/pdfs/Goodwill_written_down.pdf</a>
	30	FDA Cardio Renal Advisory Committee to Review Daiichi Sankyo, Lilly Drug Prasugrel view full story						<a href="http://www.dsi.com/news/pdfs/Prasugrel_FDA_Ad_Com123108.pdf">http://www.dsi.com/news/pdfs/Prasugrel_FDA_Ad_Com123108.pdf</a>
	31	Prasugrel Receives Positive Opinion from the European Committee for Medicinal Products for Human Use (CHMP) view full story						<a href="http://www.dsi.com/news/pdfs/Prasugrel_CHMP_Positive_Opinon_Release121708.pdf">http://www.dsi.com/news/pdfs/Prasugrel_CHMP_Positive_Opinon_Release121708.pdf</a>
	32	Daiichi Sankyo, Inc. Awarded Prestigious NCOA Certification for National Under Pressure™ Hypertension Management Program view full story						<a href="http://www.dsi.com/news/pdfs/DSNA08000373_NCOA_Certification_Press_Release12.pdf">http://www.dsi.com/news/pdfs/DSNA08000373_NCOA_Certification_Press_Release12.pdf</a>
	33	New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients with Non-Valvular Atrial Fibrillation view full story						<a href="http://www.dsi.com/news/pdfs/DU-176b_PHASE_TWO_ASH_DS_Release_120508_2.pdf">http://www.dsi.com/news/pdfs/DU-176b_PHASE_TWO_ASH_DS_Release_120508_2.pdf</a>
	34	Daiichi Sankyo Initiates Phase III Trial of its Investigational Factor Xa Inhibitor, DU-176b, in Patients with Atrial Fibrillation view full story						<a href="http://www.dsi.com/news/pdfs/DU_176b_PHASE_THREE_AF_Start_120508_2.pdf">http://www.dsi.com/news/pdfs/DU_176b_PHASE_THREE_AF_Start_120508_2.pdf</a>
	35	Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients with Heterozygous Familial Hypercholesterolemia view full story						<a href="http://www.dsi.com/news/pdfs/Welchol_AHA_Press_release.pdf">http://www.dsi.com/news/pdfs/Welchol_AHA_Press_release.pdf</a>
	36	ArQule and Daiichi Sankyo Enter into Strategic R&D Partnership to Progress Novel Compounds to Target Cancer view full story						<a href="http://www.dsi.com/news/pdfs/ArQule_Daiichi_Sankyo%20_2_.pdf">http://www.dsi.com/news/pdfs/ArQule_Daiichi_Sankyo%20_2_.pdf</a>
	37	Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death view full story						<a href="http://www.dsi.com/news/pdfs/HOS_MI_n_Survival_ISPOR_Fnl1104.pdf">http://www.dsi.com/news/pdfs/HOS_MI_n_Survival_ISPOR_Fnl1104.pdf</a>
	38	Daiichi Sankyo and Lilly Respond to Speculation On Status of Prasugrel New Drug Application view full story						<a href="http://www.dsi.com/news/pdfs/Prasugrel_Statement.pdf">http://www.dsi.com/news/pdfs/Prasugrel_Statement.pdf</a>
	39	FDA Continues to Review Prasugrel New Drug Application view full story						<a href="http://www.dsi.com/news/pdfs/Prasugrel_PDUIFA.PDF">http://www.dsi.com/news/pdfs/Prasugrel_PDUIFA.PDF</a>
	40	Daiichi Sankyo, Inc. Files Supplemental New Drug Application for AZOR® as Initial Therapy for High Blood Pressure view full story						<a href="http://www.dsi.com/news/pdfs/AZOR_sNDA_Initial_Therapy_Press_Release_FINAL09.pdf">http://www.dsi.com/news/pdfs/AZOR_sNDA_Initial_Therapy_Press_Release_FINAL09.pdf</a>
	41	New Crossover Study Shows Prasugrel Significantly Reduced Platelet Aggregation in Patients with Acute Coronary Syndromes Compared with Clopidogrel at High Doses view full story						<a href="http://www.dsi.com/news/pdfs/ACAPULCO_Release.pdf">http://www.dsi.com/news/pdfs/ACAPULCO_Release.pdf</a>
	42	Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI. Compared with Clopidogrel view full story						<a href="http://www.dsi.com/news/pdfs/TRITON_Spontaneous_Procedural_MI_Release_ESC.p">http://www.dsi.com/news/pdfs/TRITON_Spontaneous_Procedural_MI_Release_ESC.p</a>
	43	Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b view full story						<a href="http://www.dsi.com/news/pdfs/Clinical_Study_Oral_Factor.pdf">http://www.dsi.com/news/pdfs/Clinical_Study_Oral_Factor.pdf</a>
	44	Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel view full story						<a href="http://www.dsi.com/news/pdfs/TRITON_Diabetics_Manuscript_Release.pdf">http://www.dsi.com/news/pdfs/TRITON_Diabetics_Manuscript_Release.pdf</a>
	45	Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events view full story						<a href="http://www.dsi.com/news/pdfs/Recurrent_Events_Manuscript_Press%20Release_FINAL.pdf">http://www.dsi.com/news/pdfs/Recurrent_Events_Manuscript_Press%20Release_FINAL.pdf</a>
	46	FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel view full story						<a href="http://www.dsi.com/news/pdfs/Prasugrel_FDA_Review_Extension.pdf">http://www.dsi.com/news/pdfs/Prasugrel_FDA_Review_Extension.pdf</a>
	47	National Under Pressure™ Hypertension Disease Management Program Now Specifically Tailored For African Americans view full story						<a href="http://www.dsi.com/news/pdfs/Under_Pressure_Press_Release.pdf">http://www.dsi.com/news/pdfs/Under_Pressure_Press_Release.pdf</a>
	48	Nuevo Estudio Muestra que el Benicar® (Olmesartan Medoxomil) Revierte los Daños a Vasos Sanguíneos Independientemente de la Disminución de la Presión Arterial view full story						<a href="http://www.dsi.com/news/pdfs/VIOS_Release_REVISED.pdf">http://www.dsi.com/news/pdfs/VIOS_Release_REVISED.pdf</a>
	49	New Study Shows Benicar®(olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering view full story						<a href="http://www.dsi.com/news/pdfs/VIOS_Release_FINAL.pdf">http://www.dsi.com/news/pdfs/VIOS_Release_FINAL.pdf</a>
	50	Ranbaxy to bring in Daiichi Sankyo as Majority Partner. Strategic Combination creates Innovator and Generic Pharma Powerhouse view full story						<a href="http://www.dsi.com/news/pdfs/Ranbaxy_press_release_final.pdf">http://www.dsi.com/news/pdfs/Ranbaxy_press_release_final.pdf</a>
	51	New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder view full story						<a href="http://www.dsi.com/news/pdfs/ADA_Bile_Acid_Sequestant_Release.pdf">http://www.dsi.com/news/pdfs/ADA_Bile_Acid_Sequestant_Release.pdf</a>
	52	Welchol™ Lowered A1C by A Mean 1% or Greater when Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47% of Patients Evaluated view full story						<a href="http://www.dsi.com/news/pdfs/Welchol_NLA_Data_Release.pdf">http://www.dsi.com/news/pdfs/Welchol_NLA_Data_Release.pdf</a>
	53	Daiichi Sankyo Announces Acquisition of Biotech Firm U3 Pharma AG view full story						<a href="http://www.dsi.com/news/pdfs/Final_Utopia_Press_Release.pdf">http://www.dsi.com/news/pdfs/Final_Utopia_Press_Release.pdf</a>
	54	Data from Pooled Analyses Demonstrate Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes view full story						<a href="http://www.dsi.com/news/pdfs/AACE_final_WelChol_data_release.pdf">http://www.dsi.com/news/pdfs/AACE_final_WelChol_data_release.pdf</a>
	55	AZOR™ Reduces Blood Pressure in Difficult to Treat Special Populations view full story						<a href="http://www.dsi.com/news/pdfs/AZOR_ASH_Press_Release_FINAL.pdf">http://www.dsi.com/news/pdfs/AZOR_ASH_Press_Release_FINAL.pdf</a>
	56	New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR® and BENICAR HCT® view full story						<a href="http://www.dsi.com/news/pdfs/Benicar_ASH_Release_FINAL.pdf">http://www.dsi.com/news/pdfs/Benicar_ASH_Release_FINAL.pdf</a>
	57	Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-promotion Agreement view full story						<a href="http://www.dsi.com/news/pdfs/Forest_DSI_CoPromotion_Termination.pdf">http://www.dsi.com/news/pdfs/Forest_DSI_CoPromotion_Termination.pdf</a>
	58	Welchol® Added to the American College of Endocrinology/American Association of Clinical Endocrinologists. "Road Maps to Achieve Glycemic Control in Patients with Type 2 Diabetes Mellitus" view full story						<a href="http://www.dsi.com/news/pdfs/AACE_Road_Map_Press_Release_Welcho.pdf">http://www.dsi.com/news/pdfs/AACE_Road_Map_Press_Release_Welcho.pdf</a>
	59	Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel view full story						<a href="http://www.dsi.com/news/pdfs/ACC_stent_analysis_APPROVED.pdf">http://www.dsi.com/news/pdfs/ACC_stent_analysis_APPROVED.pdf</a>
	60	FDA grants priority review for Daiichi Sankyo, Lilly drug, prasugrel view full story						<a href="http://www.dsi.com/news/pdfs/Prasugrel_FDA_Grants_Priority_Review%20_2_.pdf">http://www.dsi.com/news/pdfs/Prasugrel_FDA_Grants_Priority_Review%20_2_.pdf</a>
	61	Daiichi Sankyo, Lilly Submit Marketing Authorization Application for Investigational Oral Antiplatelet Drug, Prasugrel, to European Medicines Agency view full story						<a href="http://www.dsi.com/news/pdfs/EMA_SUBMIT_FINAL_APPROVED.pdf">http://www.dsi.com/news/pdfs/EMA_SUBMIT_FINAL_APPROVED.pdf</a>
	62	Welchol™ (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes view full story						<a href="http://www.dsi.com/news/pdfs/Welchol_final_press_release.pdf">http://www.dsi.com/news/pdfs/Welchol_final_press_release.pdf</a>
	63	Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration view full story						<a href="http://www.dsi.com/news/pdfs/Final_Prasugrel_NDAsubmissionpressrelease.pdf">http://www.dsi.com/news/pdfs/Final_Prasugrel_NDAsubmissionpressrelease.pdf</a>
	64	State Highlights Daiichi Sankyo During Life Sciences Week view full story						<a href="http://www.dsi.com/news/pdfs/Corzine_DSI_press_release_11_29_07.doc">http://www.dsi.com/news/pdfs/Corzine_DSI_press_release_11_29_07.doc</a>
	65	In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack view full story						<a href="http://www.dsi.com/news/pdfs/TRITONFinalRelease.pdf">http://www.dsi.com/news/pdfs/TRITONFinalRelease.pdf</a>
	66	Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel view full story						<a href="http://www.dsi.com/news/pdfs/TRILOGY.pdf">http://www.dsi.com/news/pdfs/TRILOGY.pdf</a>
	67	Study Protocols Will be Amended in Two Small Early-Phase Prasugrel Studies view full story						<a href="http://www.dsi.com/news/pdfs/TABNTABMReleaseFinal.pdf">http://www.dsi.com/news/pdfs/TABNTABMReleaseFinal.pdf</a>
	68	Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR™ view full story						<a href="http://www.dsi.com/news/pdfs/AZOR_Co_Pro_Joint_Release_Final_10_12_07.pdf">http://www.dsi.com/news/pdfs/AZOR_Co_Pro_Joint_Release_Final_10_12_07.pdf</a>
	69	Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize.The company discusses increasing New Jersey life sciences jobs with Congressman Rodney Frelinghuysen view full story						<a href="http://www.dsi.com/news/pdfs/Frelinghuysen_DSI_press_release_final.pdf">http://www.dsi.com/news/pdfs/Frelinghuysen_DSI_press_release_final.pdf</a>
	70	AZOR™ Receives FDA Approval for Treatment of High Blood Pressure. Powerful New Combination Treatment Option Reduces Mean Systolic Blood Pressure Up to 30 Points view full story						<a href="http://www.dsi.com/news/pdfs/AZOR_Press_Release_9_27_07_FINAL_01.pdf">http://www.dsi.com/news/pdfs/AZOR_Press_Release_9_27_07_FINAL_01.pdf</a>
	71	New Survey Reveals Many Adults with High Cholesterol Fail to Take Necessary Steps to Improve Their Condition view full story						<a href="http://www.dsi.com/news/pdfs/Welchol_Survey_2007Release_8_29_07_FINAL.pdf">http://www.dsi.com/news/pdfs/Welchol_Survey_2007Release_8_29_07_FINAL.pdf</a>
	72	Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of AZOR view full story						<a href="http://www.dsi.com/news/pdfs/LOI_release_AZOR_FINAL.pdf">http://www.dsi.com/news/pdfs/LOI_release_AZOR_FINAL.pdf</a>
	73	New study demonstrates Colesevelam HCl lowers both A1C and LDL cholesterol in patients with uncontrolled Type 2 diabetes mellitus on Metformin-based regimen view full story						<a href="http://www.dsi.com/news/pdfs/ADA_Press_Release_Final.pdf">http://www.dsi.com/news/pdfs/ADA_Press_Release_Final.pdf</a>
	74	Colesevelam HCl Combined With Metformin or with Sulfonylurea-based Therapy Significantly Lowers Blood Glucose (A1C) in Patients with Type 2 Diabetes view full story						<a href="http://www.dsi.com/news/pdfs/AACE_Press_Release_FINAL.pdf">http://www.dsi.com/news/pdfs/AACE_Press_Release_FINAL.pdf</a>
	75	Benicar HCT® Reductions in seated systolic blood pressure for Stage 2 patients compared with Amlodipine benazepril view full story						<a href="http://www.dsi.com/news/pdfs/ASH_Benicar_HCT_Release.pdf">http://www.dsi.com/news/pdfs/ASH_Benicar_HCT_Release.pdf</a>
	76	Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007) view full story						<a href="http://www.dsi.com/news/pdfs/AZOR_ASH_Press_Release.pdf">http://www.dsi.com/news/pdfs/AZOR_ASH_Press_Release.pdf</a>
	77	Enrollment Completed in Pivotal Phase III Study Comparing Prasugrel to Clopidogrel in Patients with Acute Coronary Syndrome view full story						<a href="http://www.dsi.com/news/pdfs/TRITON-TIMI.pdf">http://www.dsi.com/news/pdfs/TRITON-TIMI.pdf</a>

Section	Reference	Page Name	Template	Migrate	New Copy	Description	Existing URL	Example URLs
	78	Daiichi Sankyo, Inc. Announces Filing of Supplemental New Drug Application for WelChol in the Treatment of Type 2 Diabetes Mellitus view full story						<a href="http://www.dsi.com/news/pdfs/welcholsnda.pdf">http://www.dsi.com/news/pdfs/welcholsnda.pdf</a>
	79	Daiichi Sankyo, Inc. Announces Filing of New Drug Application for Amlodipine Besylate/ Olmesartan Medoxomil Combination for the Treatment of Hypertension view full story						<a href="http://www.dsi.com/news/pdfs/8663filing.pdf">http://www.dsi.com/news/pdfs/8663filing.pdf</a>
	80	New Study Shows Prasugrel Achieves Faster Onset and Higher Levels of Platelet Inhibition than Clopidogrel at Approved or Higher Doses view full story						<a href="http://www.dsi.com/news/pdfs/TAAZ%20USates%20Fine%2010%2023%2006.pdf">http://www.dsi.com/news/pdfs/TAAZ%20USates%20Fine%2010%2023%2006.pdf</a>
	81	Sankyo Pharma Inc., Daiichi Pharmaceutical Corporation, Daiichi Medical Research Complete U.S. Integration view full story						<a href="http://www.dsi.com/news/pdfs/IntegrationRelease04032006.pdf">http://www.dsi.com/news/pdfs/IntegrationRelease04032006.pdf</a>